Clinical application of the 21-gene oncotype recurrence score in an older cohort: A single center experience

BACKGROUND: In early luminal breast cancer, the Oncotype DX® Recurrence Score (RS) prognostic and predictive value with regards to chemotherapy (CHT) application benefit has been broadly validated. In older patients its value has not been deeply addressed. This study aimed to evaluate the benefits o...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiru, E.D., Grasic Kuhar, C., Oseledchyk, A., Schötzau, A., Gonzalez, M.J., Kurzeder, C., Vetter, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2023
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10375846/
https://www.ncbi.nlm.nih.gov/pubmed/37480708
http://dx.doi.org/10.1016/j.tranon.2023.101724

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10375846/
https://www.ncbi.nlm.nih.gov/pubmed/37480708
http://dx.doi.org/10.1016/j.tranon.2023.101724

Ejemplares similares